CPRX News and Press, Catalyst Pharmaceuticals Inc. From 08/14/23

CORAL GABLES, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseas...

2023-08-10 11:37:06 ET Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2023 Earnings Conference Call August 10, 2023 8:30 AM ET Company Participants Alicia Grande - Vice President, Chief Financial Officer and Treasurer Patrick McEnany - Chairman and Chief Executive Officer ...

2023-08-09 16:23:21 ET Catalyst Pharmaceuticals press release ( NASDAQ: CPRX ): Q2 Non-GAAP EPS of $0.53 beats by $0.24 . Revenue of $99.58M (+87.5% Y/Y) beats by $7.87M . Achieved all-time high total revenues of $99.6 million for Q2 2023, an 87.5% YoY increase...

Achieved Record Q2 2023 Total Net Revenues of $99.6 Million Achieved FIRDAPSE ® 2023 Second Quarter Net Revenues of $64.9 Million, a 22% Increase YOY Achieved 2023 Second Quarter GAAP EPS Diluted of $0.33 Compared to $0.20 for Q2 2022 Achieved 2023 Second Quarter N...

2023-08-08 17:35:58 ET Catalyst Pharmaceuticals ( NASDAQ: CPRX ) is scheduled to announce Q2 earnings results on Wednesday, August 9th, after market close. The consensus EPS Estimate is $0.29 (+3.6% Y/Y) and the consensus Revenue Estimate is $91.71M (+72.7% Y/Y). Over ...

Mr. McEnany will Continue to Serve as Catalyst's Non-Executive Chairman of the Board Following his Retirement Nationally Recognized Executive Recruitment Firm has been Retained to Initiate Search CORAL GABLES, Fla., July 25, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ...

CORAL GABLES, Fla., July 24, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that...

Vamorolone is a Promising Best-In-Class Dissociative Anti-Inflammatory Steroid Treatment for Duchenne Muscular Dystrophy Synergistic Novel Asset Leverages Catalyst's Expertise and Bolsters Catalyst's Rare Neuroscience Portfolio Granted FDA Fast Track, Orphan Drug Designation, an...

2023-07-04 21:39:50 ET Summary The company reported record revenues of $85.4 million in 1Q 2023, a 98% YoY increase, and expects its 2Q, 3Q, and 4Q 2023 revenues to be higher than in 1Q. The company estimates about 10% of the patients that are taking 80 mg of FIRDAPSE per day may ...

2023-07-03 10:02:15 ET Summary This is a follow-up to my previous concerns about Catalyst Pharmaceuticals' over-dependence on FIRDAPSE, as expressed in my April 2023 article. I previously discussed Catalyst's acquisition of FYCOMPA in December 2022. The current article will re...